This systematic review and meta‐analysis of randomised controlled trials (RCTs) aimed to
evaluate the efficacy, safety, and tolerability of fluvoxamine for the outpatient management of …

Abstract Glucagon-like peptide-1 (GLP-1) agonists have been successfully used in clinical
practice for the treatment of diabetes and obesity, offering significant clinical benefits …

Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …

Background Post-acute sequelae of COVID-19 (PASC) produce significant morbidity,
prompting evaluation of interventions that might lower risk. Selective serotonin reuptake …

Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro …

For decades, concerns have been raised about the clinical trials enterprise in the US, 1 from
their high costs and lengthy time courses to their narrowness in scope and lack of …

Background Child and adolescent antidepressant use increased post-pandemic, but it is
unknown if this disproportionally affected those who develop post-acute sequelae of …

Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide
as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce …

The rapid development of vaccines to combat severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infections has been critical to reduce the severity of COVID-19 …

Background: Recent research suggests that selective serotonin reuptake inhibitors (SSRIs)
may reduce mortality in COVID-19 patients; however, research into their benefits for elderly …